In an attempt to diversify its portfolio, Moderna has entered into a strategic multi-platform collaboration with Immatics to develop new therapies for cancer patients with high unmet need. Through the deal, which could be worth up to US$1.7 B, the companies will leverage both of their technologies to develop a range of therapeutic modalities including bispecifics, cell therapies and cancer vaccines. The collaboration marks yet another move by Moderna to expand its product portfolio beyond COVID-19, as demand for its mRNA vaccine starts to dwindle.